Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 37.34M shares rose 44.3% year over year, ahead of the +18.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 21.0% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +44.3% holds above the trailing-twelve-month pace of +18.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.34M+21.0% QoQ
Last fiscal yearDec 2025
27.7M+7.1% YoY
LTMMar 2026
30.55M+18.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.3%——
1 year+7.1%——
3-year CAGR+3.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
27.7M USD
Year-over-year change
+7.1%
4-year CAGR
+2.5%

Weighted Avg Shares (Diluted) vs competitors

How CTNM compares with its peers on the latest reported figures

  • CTNM's LTM Mar 2026 weighted avg shares (diluted) of 30.55M shares is the 6th highest of the 8 companies compared; the peer median is 43.04M shares.
  • Its year-over-year change of +18.4% is the 2nd highest of 7, against a peer median of +7.1%.
  • Over three fiscal years its annual growth of +3.3% compares with a peer median of +5.5%.
CTNM Competitors Peer median
Weighted Avg Shares (Diluted) for CTNM and competitors
Company Period LTM YoY 3-year CAGR
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
Peer median (excluding CTNM) 43.04M+7.1%+5.5%

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050M00
Cost of Revenue000258K0
Gross Profit0050M(258K)0
Gross Margin——100.0%——
Research & Development22.36M16.89M27.6M38.16M51.52M
Selling, General & Admin6.29M5.83M6.32M12.47M16.54M
Operating Expenses28.65M22.72M66.08M50.64M68.06M
Depreciation & Amortization325K329K195K258K323K
EBITDA(28.34M)(23.54M)23.57M(42M)(59.66M)
EBITDA Margin——47.1%——
Operating Income(28.65M)(22.72M)(16.08M)(50.89M)(68.06M)
Operating Margin——-32.2%——
Interest Income77K761K4.61M8.91M8.25M
Interest Expense332K388K208K00
Other Income / Expenses(354K)(1.53M)39.25M8.64M8.08M
Income Before Tax(29M)(24.25M)23.17M(42.26M)(59.98M)
Pre-Tax Margin——46.3%——
Income Tax Expense00450K00
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Net Margin——45.4%——
EPS (Basic)(1.15)(0.97)0.13(1.63)(2.17)
EPS (Diluted)(1.15)(0.97)0.13(1.63)(2.17)
Weighted Avg Shares25.13M25.13M25.13M25.85M27.7M
Weighted Avg Shares (Diluted)25.13M25.13M25.13M25.85M27.7M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.